Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.39 |
| ▸ | MTOR | P42345 | 6/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448068 | 0.88 | CYP11B2 (0.34) | PIK3CAMTORCDK2KCNH2 | |
| SCHEMBL14092794 | 0.87 | CDK2 (0.39) | PIK3CAMTORAKT1CDK2KCNH2 | |
| SCHEMBL4246503 | 0.87 | ALDH1A1 (0.38) | PIK3CAMTORCDK2KCNH2JAK2 | |
| SCHEMBL4426967 | 0.85 | CDK2 (0.38) | PIK3CAMTORAKT1CDK2KCNH2 | |
| SCHEMBL4249428 | 0.85 | CDK2 (0.39) | PIK3CACDK2JAK2JAK1MAPK14 | |
| SCHEMBL4251746 | 0.84 | PIK3CA (0.36) | PIK3CAMTORAKT1JAK2JAK1 | |
| SCHEMBL4968420 | 0.84 | PIK3CA (0.35) | PIK3CAMTORAKT1JAK2JAK1 | |
| SCHEMBL3937870 | 0.81 | MAPK1 (0.48) | CDK2KCNH2JAK2JAK1MAPK14 | |
| SCHEMBL4431054 | 0.78 | MAPK8 (0.42) | CDK2KCNH2JAK2JAK1MAPK14 | |
| SCHEMBL4425795 | 0.78 | CDK2 (0.50) | CDK2KCNH2JAK2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | claimed |
| EP-1945628-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | claimed |
| WO-2007040440-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | claimed |
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | disclosed |
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | disclosed |
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | disclosed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | disclosed |
| EP-2419425-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| EP-1945628-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002245-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002245-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007040440-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | GSK3B, GSK3A, MAPT | PIK3CA 42/4885MTOR 18/4885AKT1 15/4885 |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | GSK3A, GSK3B, PYGB | PIK3CA 193/4885MTOR 215/4885AKT1 27/4885 |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | DPYD, TYMS, TYMP | PIK3CA 2569/4885MTOR 2035/4885AKT1 1726/4885 |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | GSK3B, GSK3A, STK3 | PIK3CA 272/4885MTOR 144/4885AKT1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.